JP2005501801A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501801A5
JP2005501801A5 JP2002563882A JP2002563882A JP2005501801A5 JP 2005501801 A5 JP2005501801 A5 JP 2005501801A5 JP 2002563882 A JP2002563882 A JP 2002563882A JP 2002563882 A JP2002563882 A JP 2002563882A JP 2005501801 A5 JP2005501801 A5 JP 2005501801A5
Authority
JP
Japan
Prior art keywords
disease
neurological
formulation
seizure
manifestations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2002563882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501801A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/003096 external-priority patent/WO2002064085A2/en
Publication of JP2005501801A publication Critical patent/JP2005501801A/ja
Publication of JP2005501801A5 publication Critical patent/JP2005501801A5/ja
Ceased legal-status Critical Current

Links

JP2002563882A 2001-02-02 2002-01-24 フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療 Ceased JP2005501801A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26619401P 2001-02-02 2001-02-02
PCT/US2002/003096 WO2002064085A2 (en) 2001-02-02 2002-01-24 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Publications (2)

Publication Number Publication Date
JP2005501801A JP2005501801A (ja) 2005-01-20
JP2005501801A5 true JP2005501801A5 (enExample) 2005-12-22

Family

ID=23013568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002563882A Ceased JP2005501801A (ja) 2001-02-02 2002-01-24 フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療

Country Status (17)

Country Link
US (2) US6908902B2 (enExample)
EP (1) EP1471871B1 (enExample)
JP (1) JP2005501801A (enExample)
KR (1) KR100896971B1 (enExample)
AT (1) ATE361089T1 (enExample)
CA (1) CA2437333A1 (enExample)
CY (1) CY1106733T1 (enExample)
DE (1) DE60219961T8 (enExample)
DK (1) DK1471871T3 (enExample)
ES (1) ES2284858T3 (enExample)
MX (1) MXPA03006952A (enExample)
NO (1) NO20033440L (enExample)
NZ (1) NZ548578A (enExample)
PT (1) PT1471871E (enExample)
RU (1) RU2317086C2 (enExample)
WO (1) WO2002064085A2 (enExample)
ZA (1) ZA200306818B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
JP2005501801A (ja) * 2001-02-02 2005-01-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療
CA2459146A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
EP1815854A1 (en) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Treatment of dyskenesia
CA2499200A1 (en) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Use of compounds in the treatment of dyskinesia
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
JPWO2007020922A1 (ja) * 2005-08-17 2009-02-26 創 戸苅 脳疾患の治療剤および予防剤
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
AU2007285763B2 (en) * 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2150248A4 (en) * 2007-01-16 2011-06-29 Univ Johns Hopkins GLUTAMATE RECEPTOR ANTAGONISTS AND METHOD OF USE
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
RU2335296C1 (ru) * 2007-06-26 2008-10-10 Сергей Марович Дудкин Фармацевтическая композиция для профилактики и лечения неврологических заболеваний
CA3184105A1 (en) * 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
NZ271181A (en) 1993-07-19 1998-06-26 Amgen Inc Protein protection; method for stabilising aerosolised proteins by adding a water-soluble polar organic compound to the aqueous solution prior to aerosolisation
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
WO1995017406A1 (en) * 1993-12-23 1995-06-29 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
ES2273434T3 (es) 1997-07-23 2007-05-01 Roche Diagnostics Gmbh Obtencion de la eritropoyetina mediante activacion genica endogena.
ES2208798T3 (es) 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
EP1065931A4 (en) * 1998-04-02 2006-10-11 Avicena Group Inc COMPOSITIONS CONTAINING CREATINE COMBINED WITH A SECOND AGENT
DK1088084T3 (da) 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
US6583172B1 (en) * 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
CA2270795A1 (en) * 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
JP2005501801A (ja) * 2001-02-02 2005-01-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療

Similar Documents

Publication Publication Date Title
RU2003124059A (ru) Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина
JP7833272B2 (ja) 神経変性疾患のための治療薬
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
Kurczynski Hyperekplexia
IL157591A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
JP2004523555A5 (enExample)
JP2017535569A5 (enExample)
RU2006110545A (ru) Новое медицинское применение избирательных антагонистов св1-рецептора
Shahar et al. Sporadic major hyperekplexia in neonates and infants: clinical manifestations and outcome
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
Yamanaka et al. Over 10 years of isolated autonomic failure preceding dementia and Parkinsonism in 2 patients with Lewy body disease
CN109363878A (zh) 一种优化型骨科临床手术器械
Hamidi et al. Contribution of Sensory Systems to Static Balance in Elderly Women following Exercise Training (Part Two: Hippotherapy vs Aquatic Exercise): Quasi-experimental Study
Knight The role of primary cilia in cartilage health and disease
JP2022525706A5 (enExample)
Chitambira Use of an optokinetic chart stimulation intervention for restoration of voluntary movement, postural control and mobility in acute stroke patients and one post intensive care polyneuropathy patient: A case series
ATE539763T1 (de) Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit
AU2002247203B2 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
GB202418144D0 (en) Antisense oligonucleotides for the treatment of parkinson's disease
Mahowald et al. REM sleep behavior disorder
Wang Role of Tai Chi in osteoarthritis
Patel et al. To Compare Mental Practice with Motor Imagery and Mirror Therapy on Hand Function in Stroke Patients
Bove et al. 16.3 Postural responses to continuous asymmetric neckmuscle vibrations in patients with cervical dystonia
Bakker et al. 16.21 Postural responses to multidirectional stanceperturbations in cerebellar ataxia
Rahmlow et al. 113. Unusual spinal epidural cyst mimicking Hirayama disease